Quick Answer
Karyopharm Therapeutics Inc. reported Operating Income Loss of -$90.71 million for the year ending 2025.
- Karyopharm Therapeutics Inc. showed an increase of +24.1% in Operating Income Loss from 2024 to 2025.
- This data is from Karyopharm Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Karyopharm Therapeutics Inc.'s Operating Income Loss has declined by 779.7%.
- Historical annual values: Fiscal year 2025: -$90.71 million | Fiscal year 2024: -$119.44 million | Fiscal year 2023: -$129.54 million | Fiscal year 2022: -$142.20 million | Fiscal year 2021: -$98.27 million | Fiscal year 2020: -$171.85 million | Fiscal year 2019: -$189.28 million | Fiscal year 2018: -$179.88 million | Fiscal year 2017: -$130.54 million | Fiscal year 2016: -$110.73 million | Fiscal year 2015: -$119.08 million | Fiscal year 2014: -$75.85 million | Fiscal year 2013: -$33.95 million | Fiscal year 2012: -$15.89 million | Fiscal year 2011: -$10.31 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: